Cargando…

Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors

Undeniably, immunotherapy has markedly improved the survival rate of cancer patients. The scenario is no different in lung cancer, where multiple treatment options are now available and the inclusion of immunotherapy yields better clinical benefits than previously used chemotherapeutic strategies. O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vaseq, Rohulla, Sharma, Amit, Li, Yutao, Schmidt-Wolf, Ingo G. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054817/ https://www.ncbi.nlm.nih.gov/pubmed/36982701 http://dx.doi.org/10.3390/ijms24065626

Ejemplares similares

Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer
por: Dehno, Mojgan Naghizadeh, et al.
Publicado: (2020)

A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines
por: Li, Yutao, et al.
Publicado: (2022)

PD-1 blockade enhances cytokine-induced killer cell-mediated cytotoxicity in B-cell non-Hodgkin lymphoma cell lines
por: Li, Yutao, et al.
Publicado: (2021)

Increase of Antitumoral Effects of Cytokine-Induced Killer Cells by Antibody-Mediated Inhibition of MICA Shedding
por: Wu, Xiaolong, et al.
Publicado: (2020)

Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials
por: Zhang, Ying, et al.
Publicado: (2021)

Cytokine-induced killer cells are type II natural killer T cells
por: Gütgemann, Stefan, et al.
Publicado: (2007)

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
por: Wang, Chengdi, et al.
Publicado: (2021)

Effect of chaetocin on renal cell carcinoma cells and cytokine-induced killer cells
por: Rombo, Roman, et al.
Publicado: (2016)

Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma
por: Esser, Laura, et al.
Publicado: (2016)

High Expression of Cannabinoid Receptor 2 on Cytokine-Induced Killer Cells and Multiple Myeloma Cells
por: Garofano, Francesca, et al.
Publicado: (2020)

Cytokine-Induced Killer Cells in Combination with Heat Shock Protein 90 Inhibitors Functioning via the Fas/FasL Axis Provides Rationale for a Potential Clinical Benefit in Burkitt’s lymphoma
por: Ge, Fangfang, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022)

Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma
por: Zhang, Ying, et al.
Publicado: (2020)

NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation
por: Wu, Xiaolong, et al.
Publicado: (2021)

Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Gastrointestinal Tumors
por: Jäkel, Clara E., et al.
Publicado: (2014)

Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
por: Jia, Yunlong, et al.
Publicado: (2020)

Aging of the Immune System: Focus on Natural Killer Cells Phenotype and Functions
por: Brauning, Ashley, et al.
Publicado: (2022)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Machairas, Nikolaos, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma
por: Lynch, Emer, et al.
Publicado: (2023)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Ruff, Samantha M., et al.
Publicado: (2023)

Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy
por: Garofano, Francesca, et al.
Publicado: (2019)

Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
por: Schmeel, Frederic Carsten, et al.
Publicado: (2014)

LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
por: Ibrahim, Rebecca, et al.
Publicado: (2023)

Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
por: Bertucci, François, et al.
Publicado: (2021)

Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges
por: Poggi, Alessandro, et al.
Publicado: (2021)

Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma
por: Jäkel, Clara E., et al.
Publicado: (2012)

Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab
por: Bukamur, Hazim, et al.
Publicado: (2020)

Landscape of immune checkpoint inhibitor-related adverse events in Chinese population
por: Li, Li, et al.
Publicado: (2020)

Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer
por: Nagaraj, Srinivas, et al.
Publicado: (2004)

The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma
por: Wang, Jian, et al.
Publicado: (2021)

Improved Activation toward Primary Colorectal Cancer Cells by Antigen-Specific Targeting Autologous Cytokine-Induced Killer Cells
por: Schlimper, Claudia, et al.
Publicado: (2012)

Enhanced Cancer Therapy Using an Engineered Designer Cytokine Alone and in Combination With an Immune Checkpoint Inhibitor
por: Pradhan, Anjan K., et al.
Publicado: (2022)

Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors
por: Farooqui, Naba, et al.
Publicado: (2022)

Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors
por: Zhu, Yingming, et al.
Publicado: (2018)

The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors
por: Alimonti, Paolo, et al.
Publicado: (2023)

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
por: Liu, Qingxu, et al.
Publicado: (2023)

The Cytokine Expression in Patients with Cardiac Complication after Immune Checkpoint Inhibitor Therapy
por: Tsuruda, Toshihiro, et al.
Publicado: (2020)

The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
por: Wang, Min, et al.
Publicado: (2021)

Killer to cure: Expression and production costs calculation of tobacco plant‐made cancer‐immune checkpoint inhibitors
por: Ridgley, Laura A., et al.
Publicado: (2023)

Modelling of Immune Checkpoint Network Explains Synergistic Effects of Combined Immune Checkpoint Inhibitor Therapy and the Impact of Cytokines in Patient Response
por: Kondratova, Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fvcfg20iksdt9mc29udoe61o95